Analys

SynAct (Q3 Update): ADVANCE Approaching Full Recruitment - Redeye

{newsItem.title}

Redeye Publicerad: 31 Oct 07:23

Redeye reviews SynAct Pharma's Q3 report. The ADVANCE study is progressing and on track to enrol all patients before year-end 2025. This means topline data will be available in H1 2026, a major catalyst. The company is funded into 2027.

Länk till analysen i sin helhet: https://www.redeye.se/research/1133751/synact-q3-update-advance-approaching-full-recruitment?utm_source=finwire&utm_medium=RSS

Nyheter om SynAct Pharma

Läses av andra just nu

Om aktien SynAct Pharma

Senaste nytt